Hanwha Chemical Corporation

Abl Bio Inc.

Ares Trading S.a.

Prestige Biopharma Pte. Ltd.

Pharmabcine Inc.

Pharmabeine Inc.

Dong Heon Lee

Sung Woo Kim

Yu Bin Choi

Yong Ho Ahn

Dong In Kim

Ji Yong Yoon

Young Min Kim

Young Woo Park

Chae Ok Yun

Sang Kyung Park

Dong Eun Lee

Ji Hyun Park

Sun Kyu Kim

Kyung Duk Moon

Semi Kim

Do Yun Kim

Weon Sup Lee

Myeoung Hee Jang

Jun Ki Hong

Sang Ryeol Shim

Jin San Yoo

Kwi Hwa Kim

Jae Won Jeon

Sang Seok Koh

Young Guen Kwon

Kyung Jae Kang

Byung Je Sung

Su Yeon Ryu

Jung Tae Lee

Eun A Kim

So Young Choi

Soo Kwang Kim

Bo Jeong Pyun

JinWon Jung

Weon Kyoo You

Hyun Sook Jang

Joon Chul Lee

Jin Geun Kwon

Hyun Bo Shim

Yong Gyu Son

Mi Hee Park

Il Sun Lee

Hee Jung Jun

Jin Hyung Ahn

Yang Soon Lee

Sam Sook Sul

Dong Sup Lee

Jeong Eun Kang

Geun Bae Rha

Too Hyon Cho

Nahm Ju Kim

Hyeon Mi Yoo

The prevent invention relates a method and apparatus based on neural network for pre-diagnosing defect and fire in battery cell. A method based on neural network for pre-diagnosing defect and fire in battery cell in an apparatus for pre-diagnosing defect and fire in battery cell is proposed, the method including collecting, by the battery cell defect and fire pre-diagnosis apparatus, data including at least one of chemical composition, current, voltage, and temperature data measured for each predetermined time interval within each charge and discharge cycle while charging and discharging a plurality of batteries; training, by the battery to cell defect and fire pre-diagnosis apparatus, the neural network by inputting the collected data to the neural network; and predicting, by the battery cell defect and fire pre-diagnosis apparatus, a battery deviated from a main cluster of the neural network as defective.

Method and apparatus based on neural network for pre-diagnosing defect and fire in battery cell

The present invention relates to a bicistronic expression vector for antibody expression, an animal cell transfected with the expression vector, and a method for producing an antibody including culturing the animal cell, in which the expression vector includes a first expression cassette including 'promoter-UTR-intron-antibody light chain gene-polyA' and a second expression cassette including 'promoter-UTR-intron-antibody heavy chain gene-internal ribosome entry site (IRES)-amplification gene-polyA'. An expression vector capable of expressing a desired antibody with high efficiency can be constructed using the bicistronic expression vector including an intron for antibody expression according to the present invention, and the expression vector can produce the antibody by culturing the transfected animal cell with stability and high efficiency.

Bicistronic expression vector for antibody expression and method for producing antibody using same

The present invention relates to a novel dual-targeting protein comprising: a protein that binds specifically to delta-like ligand 4 (DLL4); and an antibody that binds specifically to vascular endothelial cell growth factor (VEGF).

Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof

The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (DLL4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and Notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.

Monoclonal antibody binding specifically to DLL4 and use thereof

The present invention relates to a vector comprising a polynucleotide encoding a modified glutamine synthetase (GS), and a method for preparing a target protein employing the same. More particularly, the present invention relates to a modified GS having an increased sensitivity to a glutamine synthetase (GS) inhibitor, a polynucleotide encoding the modified GS, a vector comprising the polynucleotide, a transformant comprising the vector, and a method for preparing a target protein using the transformant.

Expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same

The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.

Human monoclonal antibody that specifically binds to VCAM-1 and a composition for treating an inflammatory disease or a cancer comprising the same

The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.

Human recombinant monoclonal antibody that specifically binds to VCAM-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells

Growing community of inventors

Daejeon, South Korea

Dong Heon Lee